Your browser is no longer supported. Please, upgrade your browser.
Settings
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.67 Insider Own2.60% Shs Outstand48.19M Perf Week-0.23%
Market Cap1.26B Forward P/E- EPS next Y-2.81 Insider Trans-11.24% Shs Float45.85M Perf Month-0.65%
Income-121.10M PEG- EPS next Q-0.31 Inst Own75.90% Short Float11.51% Perf Quarter-11.57%
Sales29.50M P/S42.70 EPS this Y1.10% Inst Trans0.30% Short Ratio6.61 Perf Half Y-27.65%
Book/sh4.73 P/B5.53 EPS next Y- ROA-31.10% Target Price46.71 Perf Year-12.40%
Cash/sh7.00 P/C3.73 EPS next 5Y- ROE-53.10% 52W Range17.80 - 45.02 Perf YTD14.90%
Dividend- P/FCF- EPS past 5Y- ROI-48.20% 52W High-41.94% Beta-
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low46.85% ATR1.66
Employees112 Current Ratio13.10 Sales Q/Q130.20% Oper. Margin- RSI (14)52.96 Volatility5.21% 8.23%
OptionableYes Debt/Eq0.15 EPS Q/Q50.10% Profit Margin- Rel Volume0.81 Prev Close26.21
ShortableYes LT Debt/Eq0.15 EarningsFeb 06 AMC Payout- Avg Volume798.22K Price26.14
Recom- SMA2010.82% SMA50-1.83% SMA200-16.41% Volume648,251 Change-0.27%
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Jan-18-19 05:45PM  Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know Zacks
12:55PM  4 Gene-Editing Technologies That Could Replace CRISPR Motley Fool
Jan-15-19 07:50AM  Today's Research Reports on Trending Tickers: Exelixis and Editas Medicine ACCESSWIRE +5.64%
Jan-11-19 05:50PM  Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know Zacks
Jan-10-19 06:05PM  Here's Why Editas Medicine Lost 16.6% in December Motley Fool
03:36PM  The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29% Motley Fool
08:15AM  4 Reasons Editas Medicine's Future Looks Really Bright Motley Fool
Jan-09-19 11:21AM  CRISPR cadre: Check out the 12 Mass. companies exploring gene editing American City Business Journals
Jan-08-19 04:33PM  Editas CEO Katrine Bosley: We take the responsibility of ... CNBC Videos
04:30PM  Radius Exceeds 2018 Financial Guidance, Provides Updates Zacks
09:54AM  Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks
09:30AM  Has Editas Medicine (EDIT) Outpaced Other Medical Stocks This Year? Zacks
08:16AM  Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day Zacks
06:01AM  Bull of the Day: Editas Medicine (EDIT) Zacks
Jan-07-19 04:57PM  Aerie's Rhopressa Succeeds in Study on Japanese Patients Zacks +7.46%
10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks
09:00AM  Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-19 06:29PM  Jazz Inks Deal with Codiak to Develop Exosome Therapeutics Zacks +5.65%
04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily
Jan-03-19 09:30AM  Novo Nordisk Boasts Strong Diabetes Presence and Pipeline Zacks -5.91%
09:15AM  2019 Starts Off in the Green Zacks
08:50AM  Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply Zacks
Jan-02-19 08:30AM  Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-18 10:29AM  Biotech markets could be very promising in 2019 Yahoo Finance Video
08:29AM  Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group Zacks
Dec-21-18 04:32PM  Why Perrigo, New Age Beverages, and Editas Medicine Slumped Today Motley Fool -20.78%
11:37AM  Why Editas Medicine Is Sinking Today Motley Fool
09:00AM  Editas Medicine Announces Transition of Chief Financial Officer GlobeNewswire
Dec-18-18 10:24PM  Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy? Insider Monkey
Dec-13-18 02:23PM  Edited Transcript of EDIT earnings conference call or presentation 7-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Dec-10-18 04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
12:42PM  Here's Why Editas Medicine Jumped 23% in November Motley Fool
09:00AM  Editas Medicine Names Cynthia Collins to Board of Directors GlobeNewswire
Dec-09-18 11:32AM  Is Editas Medicine a Buy? Motley Fool
Dec-02-18 07:35PM  Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
09:02AM  Better Buy: Editas Medicine vs. Sangamo Therapeutics Motley Fool
Nov-30-18 04:14PM  This Biotech Stock Could Launch Its First CRISPR Drug In 2022 Investor's Business Daily
10:31AM  Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018 Motley Fool
10:24AM  FDA clears Editas to test gene-editing drug in humans American City Business Journals
07:30AM  Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101 GlobeNewswire
Nov-26-18 02:46PM  Mass. biotech leaders voice alarm over report of first gene-edited babies American City Business Journals
Nov-12-18 08:30AM  Analysis: Positioning to Benefit within IDEXX Laboratories, Editas Medicine, Arconic, Cardtronics, Cloudera, and BMC Stock Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-08-18 08:00AM  Editas Medicine Makes Steady Progress in Another Solid Quarter Motley Fool
Nov-07-18 07:46PM  Cambridge's Editas asks FDA to start gene editing trial American City Business Journals +5.69%
07:37PM  Editas Medicine, Inc. (EDIT) Q3 2018 Earnings Conference Call Transcript Motley Fool
07:10PM  Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:03PM  Editas: 3Q Earnings Snapshot Associated Press
04:01PM  Editas Medicine Announces Third Quarter 2018 Results and Update GlobeNewswire
Nov-05-18 02:13PM  Here's Why CRISPR Stocks Fell as Much as 40.7% in October Motley Fool
07:55AM  5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings Zacks
Nov-03-18 08:20AM  Better Buy: Editas Medicine, Inc. vs. Intellia Therapeutics, Inc. Motley Fool
Nov-02-18 06:45PM  Editas Medicine (EDIT) Gains As Market Dips: What You Should Know Zacks
Oct-31-18 04:01PM  Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results GlobeNewswire
11:23AM  Is a Beat in Store for Editas (EDIT) This Earnings Season? Zacks
Oct-26-18 05:45PM  Editas Medicine (EDIT) Stock Moves -0.95%: What You Should Know Zacks
Oct-18-18 09:15AM  Recent Analysis Shows Lantheus, Editas Medicine, CorMedix, DXP Enterprises, Peabody Energy, and CommScope Holding Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Oct-09-18 04:35PM  Better Buy: Crispr Therapeutics AG vs. Editas Motley Fool
Oct-01-18 09:00AM  Editas Medicine Grows Scientific Leadership with Two New Appointments GlobeNewswire
Sep-27-18 06:31AM  The Greatest Healthcare Stocks of the 21st Century -- and Some That Probably Will Be Motley Fool
Sep-25-18 01:58PM  Who Owns Most Of Editas Medicine Inc (NASDAQ:EDIT)? Simply Wall St. +6.61%
Sep-21-18 11:23AM  Crispr Appears 'Crispy and Overcooked,' Says Analyst Bloomberg -7.58%
Sep-16-18 08:31AM  Is CRISPR Therapeutics AG a Buy? Motley Fool
Sep-10-18 01:58PM  Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference GlobeNewswire
01:52PM  U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing Reuters
Sep-07-18 08:18AM  Better Buy: Editas Medicine, Inc. vs. CRISPR Therapeutics Motley Fool
Sep-04-18 11:29AM  Here's Why CRISPR Stocks Rose as Much as 18.7% in August Motley Fool
Aug-31-18 02:27PM  This Start-Up Thinks It Can Tackle One of CRISPR's Biggest Obstacles Motley Fool
Aug-28-18 06:50PM  3 Stocks Your Children Will Brag About Someday Motley Fool
Aug-27-18 04:01PM  Editas Medicine Announces Transition of Chief Medical Officer GlobeNewswire
01:12PM  Gene Editing is a Major Technology to Watch InvestorPlace
07:50AM  Analysis: Positioning to Benefit within Editas Medicine, Alcoa, MaxLinear, Real Goods Solar, NII, and Preformed Line Products Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-24-18 08:16AM  3 Relatively Safe Ways to Invest in Gene Editing Motley Fool
Aug-21-18 09:40AM  Edited Transcript of EDIT earnings conference call or presentation 6-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
07:12AM  The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed Motley Fool
Aug-19-18 06:33AM  3 Hot Trends Warren Buffett Is Missing Out On -- But You Don't Have To Motley Fool
Aug-16-18 04:01PM  Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process GlobeNewswire
Aug-13-18 07:38AM  The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers Zacks
Aug-10-18 08:52AM  Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus Zacks
08:45AM  Options Traders Expect Huge Moves in Editas Medicine (EDIT) Stock Zacks
Aug-09-18 04:17PM  Editas Prepares for the Commercialization of EDIT-101 Motley Fool
Aug-08-18 01:14PM  Editas Medicine (EDIT) Q2 2018 Earnings Conference Call Transcript Motley Fool
Aug-07-18 08:00AM  Today's Research Reports on Trending Tickers: Editas Medicine and Ligand Pharmaceuticals ACCESSWIRE
Aug-06-18 06:10PM  Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:06PM  Editas: 2Q Earnings Snapshot Associated Press
04:05PM  Editas Medicine Announces Second Quarter 2018 Results and Update GlobeNewswire
04:01PM  Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101 PR Newswire
03:00PM  Editas Medicine, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 06:11PM  David Looks Ahead: 1 Massive Trend, 10 Hot Stocks, and 1 Vital Piece of Advice Motley Fool
05:43PM  FoolFest 2018: The Gardner Brothers Look Back -- and Ahead Motley Fool
Jul-30-18 04:02PM  Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results GlobeNewswire
06:50AM  Editas Medicine (EDIT) Enters Oversold Territory Zacks
Jul-28-18 04:20PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
09:03AM  Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer Motley Fool
Jul-25-18 08:00AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Editas Medicine ACCESSWIRE
Jul-24-18 04:06PM  Here's Why CRISPR Stocks Are Down as Much as 11.4% Today Motley Fool -8.23%
Jul-17-18 03:01PM  Yet Another CRISPR Worry: What Should Investors Do? Motley Fool
Jul-16-18 07:31PM  [$$] New Research Prompts Selloff in Companies Using Crispr Technology The Wall Street Journal -7.12%
02:28PM  CRISPR gene editing can cause risky collateral DNA damage - study Reuters
01:05PM  CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech Motley Fool
12:21PM  Gene-editing stocks tumble on concerns about DNA damage MarketWatch
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myer VickeshChief Technology OfficerJan 18Option Exercise11.214,00044,8404,000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 18Sale26.504,000106,0000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 17Option Exercise0.653,0001,9503,000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 17Sale26.183,00078,5400Jan 18 08:58 PM
Bosley KatrinePresident and CEOJan 08Sale25.2712,000303,2401,204,966Jan 10 04:11 PM
Hack Andrew A. F.Chief Financial OfficerJan 04Option Exercise6.487,00045,3607,000Jan 08 05:36 PM
Hack Andrew A. F.Chief Financial OfficerJan 04Sale22.487,000157,3600Jan 08 05:36 PM
Myer VickeshChief Technology OfficerDec 18Option Exercise11.214,00044,8404,000Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 18Sale27.414,000109,6400Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 17Option Exercise0.653,0001,9503,000Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 17Sale27.893,00083,6630Dec 19 04:41 PM
Bosley KatrinePresident and CEODec 03Sale31.9212,000383,0871,216,966Dec 06 04:02 PM
Hack Andrew A. F.Chief Financial OfficerNov 23Option Exercise6.485,28434,2405,284Nov 27 04:25 PM
Hack Andrew A. F.Chief Financial OfficerNov 23Sale28.155,284148,7390Nov 27 04:25 PM
Myer VickeshChief Technology OfficerNov 20Option Exercise11.214,00044,8404,000Nov 21 04:03 PM
Myer VickeshChief Technology OfficerNov 20Sale26.504,000106,0000Nov 21 04:03 PM
Myer VickeshChief Technology OfficerNov 19Option Exercise0.653,0001,9502,700Nov 21 04:03 PM
Myer VickeshChief Technology OfficerNov 19Sale28.193,00084,5790Nov 21 04:03 PM
Bosley KatrinePresident and CEONov 01Sale26.8812,000322,5081,228,966Nov 05 05:42 PM
Hack Andrew A. F.Chief Financial OfficerOct 26Option Exercise6.486,00038,8806,000Oct 30 05:05 PM
Hack Andrew A. F.Chief Financial OfficerOct 26Sale25.706,000154,2000Oct 30 05:05 PM
Myer VickeshChief Technology OfficerOct 18Option Exercise11.214,00044,8404,000Oct 19 04:01 PM
Myer VickeshChief Technology OfficerOct 18Sale29.444,000117,7600Oct 19 04:01 PM
Myer VickeshChief Technology OfficerOct 17Option Exercise0.653,0001,9503,000Oct 19 04:01 PM
Myer VickeshChief Technology OfficerOct 17Sale28.873,00086,6100Oct 19 04:01 PM
Bosley KatrinePresident and CEOOct 01Sale31.0212,000372,2931,240,966Oct 03 04:03 PM
Hack Andrew A. F.Chief Financial OfficerSep 28Option Exercise6.488,00051,8408,000Oct 02 04:02 PM
Hack Andrew A. F.Chief Financial OfficerSep 28Sale32.088,000256,6400Oct 02 04:02 PM
Myer VickeshChief Technology OfficerSep 18Option Exercise11.214,00044,8404,000Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 18Sale32.194,000128,7600Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 17Option Exercise0.653,0001,9503,000Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 17Sale32.333,00096,9900Sep 19 04:03 PM
Bosley KatrinePresident and CEOSep 04Sale32.3512,000388,2101,252,966Sep 06 04:02 PM
Hack Andrew A. F.Chief Financial OfficerAug 31Option Exercise6.4810,00064,80010,000Sep 05 04:04 PM
Hack Andrew A. F.Chief Financial OfficerAug 31Sale32.2310,000322,3000Sep 05 04:04 PM
Myer VickeshChief Technology OfficerAug 20Option Exercise11.214,00044,8403,600Aug 21 04:09 PM
Myer VickeshChief Technology OfficerAug 20Sale29.874,000119,4800Aug 21 04:09 PM
Bosley KatrinePresident and CEOAug 20Sale30.1712,000362,0081,264,966Aug 22 04:16 PM
Myer VickeshChief Technology OfficerAug 17Option Exercise0.653,0001,9503,000Aug 21 04:09 PM
Myer VickeshChief Technology OfficerAug 17Sale29.653,00088,9500Aug 21 04:09 PM
Bosley KatrinePresident and CEOAug 01Sale29.558,333246,2531,276,966Aug 03 04:01 PM
Myer VickeshChief Technology OfficerJul 18Option Exercise11.217,00078,4706,150Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 18Sale35.567,000248,8920Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Option Exercise0.657,0004,5504,000Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Sale35.717,000249,9800Jul 19 04:07 PM
Bosley KatrinePresident and CEOJul 02Sale36.298,333302,4411,285,299Jul 05 04:00 PM
Myer VickeshChief Technology OfficerJun 19Option Exercise11.217,00078,4707,000Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 19Sale38.397,000268,7300Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 18Option Exercise0.657,0004,5504,300Jun 20 04:57 PM
Myer VickeshChief Technology OfficerJun 18Sale38.127,000266,8420Jun 20 04:57 PM
Albright CharlesChief Scientific OfficerJun 13Option Exercise16.5110,000165,10010,000Jun 15 04:16 PM
Albright CharlesChief Scientific OfficerJun 13Sale35.9810,000359,8000Jun 15 04:16 PM
Hack Andrew A. F.Chief Financial OfficerJun 04Option Exercise24.603,00073,8003,000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 04Sale37.103,000111,3000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 01Option Exercise6.487,00045,3605,000Jun 05 04:08 PM
Hack Andrew A. F.Chief Financial OfficerJun 01Sale39.287,000274,9700Jun 05 04:08 PM
Bosley KatrinePresident and CEOJun 01Sale37.558,333312,8731,293,632Jun 05 04:06 PM
Albright CharlesChief Scientific OfficerMay 23Option Exercise16.5110,000165,10010,000May 25 04:31 PM
Albright CharlesChief Scientific OfficerMay 23Sale35.0010,000350,0000May 25 04:31 PM
MULLEN JAMES CDirectorMay 18Buy38.0310,000380,25210,000May 22 05:28 PM
Hopfield JessicaDirectorMay 17Buy37.286,700249,7806,700May 21 04:27 PM
Bosley KatrinePresident and CEOMay 01Sale31.958,333266,2391,301,965May 03 05:31 PM
Bosley KatrinePresident and CEOApr 02Sale32.168,333267,9691,310,298Apr 04 04:05 PM
Hack Andrew A. F.Chief Financial OfficerMar 20Option Exercise20.7228,000580,08022,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 20Sale37.8628,0001,059,9600Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 19Option Exercise6.486,00038,8806,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 19Sale37.656,000225,9000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 16Option Exercise6.486,00038,8806,000Mar 20 05:36 PM
Hack Andrew A. F.Chief Financial OfficerMar 16Sale39.436,000236,5800Mar 20 05:36 PM
Bosley KatrinePresident and CEOMar 09Sale45.009,134411,0301,318,631Mar 13 08:45 AM
Bosley KatrinePresident and CEOMar 01Sale35.728,333297,6931,327,765Mar 05 04:52 PM
Hack Andrew A. F.Chief Financial OfficerFeb 16Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 16Sale35.326,000211,9200Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Sale34.616,000207,6600Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 14Option Exercise6.486,00038,8806,000Feb 16 04:04 PM
Hack Andrew A. F.Chief Financial OfficerFeb 14Sale32.716,000196,2600Feb 16 04:04 PM
Bosley KatrinePresident and CEOFeb 01Sale36.188,333301,4511,336,098Feb 05 06:05 PM
Bosley KatrinePresident and CEOJan 30Sale40.0510,000400,5201,344,431Jan 31 04:18 PM
Bosley KatrinePresident and CEOJan 29Sale37.5310,000375,3401,354,431Jan 31 04:18 PM
Bosley KatrinePresident and CEOJan 23Sale35.283,338117,7651,364,431Jan 25 04:11 PM